AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19268614 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored behavioural treatment protocol (TBT)
Number of subjects: 122
Study 19268614 — intervention group
Group type: COMPARATOR
Intervention: Exercise based physical therapy protocol (EBT)
Number of subjects: 122
Study 19268614 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TBT and EBT
Number of subjects: 122
Study 17073988 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin care and makeup instructions from dermatologists
Number of subjects: 50
Study 17073988 — intervention group
Group type: COMPARATOR
Intervention: No specific instructions from dermatologists
Number of subjects: 50
Study 14707796 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast feeding
Number of subjects: 111
Study 14707796 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner willingness to have HIV‐1 testing
Number of subjects: 111
Study 14707796 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed feeding
Number of subjects: 111
Study 14707796 — intervention group
Group type: EXPERIMENTAL
Intervention: Not breast feeding
Number of subjects: 111
Study 14707796 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1 infection
Number of subjects: 111
Study 14707796 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight <3000 g
Number of subjects: 111
Study 14707796 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal employment
Number of subjects: 111
Study 14707796 — intervention group
Group type: EXPERIMENTAL
Intervention: Paying <$12.5 per month in house rent
Number of subjects: 111
Study 12234950 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 70
Study 12234950 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 70
Study 12234950 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide
Number of subjects: 70
Study 9885731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with grass pollen extract (9,500 BU/ml)
Number of subjects: 57
Study 9885731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 8004299 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (5 mg x 2)
Number of subjects: 47
Study 8004299 — intervention group
Group type: COMPARATOR
Intervention: Intravenous albuterol (0.5 mg)
Number of subjects: 47
Study 2591460 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g Heptaminol Adenosine Phosphate (HAP)
Number of subjects: 30
Study 2591460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1242861 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone Dipropionate (12 metered-doses per day)
Number of subjects: 20
Study 1242861 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone Isonicotinate (12 metered-doses per day)
Number of subjects: 20
Study 7441333 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminectomy followed by radiotherapy
Number of subjects: 0
Study 7441333 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study 31821452 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (7-day therapy)
Number of subjects: 472
Study 31821452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study 31775353 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement A (50 mg of blackcurrant anthocyanin)
Number of subjects: 24
Study 31775353 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement B (50 mg of blackcurrant anthocyanin plus vitamin E)
Number of subjects: 24
Study 31775353 — intervention group
Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 24
Study 28870680 — intervention group
Group type: EXPERIMENTAL
Intervention: MYC gene amplification without polysomy-8
Number of subjects: 1060
Study 28870680 — intervention group
Group type: COMPARATOR
Intervention: MYC amplification with polysomy-8, polysomy-8 only, and normal MYC without polysomy-8
Number of subjects: 1060
Study 28870680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear Myc protein expression
Number of subjects: 1060
Study 27509519 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet
Number of subjects: 39
Study 27509519 — intervention group
Group type: COMPARATOR
Intervention: Australian Guide to Healthy Eating (AGHE)
Number of subjects: 39
Study 24802722 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7325 2 mg
Number of subjects: 16
Study 24802722 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7325 10 mg
Number of subjects: 16
Study 24802722 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 16
Study 24802722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 22092918 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriatic lesions
Number of subjects: 111
Study 22092918 — intervention group
Group type: COMPARATOR
Intervention: Contralateral uninvolved sites
Number of subjects: 111
Study 19403903 — intervention group
Group type: EXPERIMENTAL
Intervention: T12PR12 group (telaprevir, peginterferon alfa‐2a, and ribavirin for 12 weeks)
Number of subjects: 334
Study 19403903 — intervention group
Group type: EXPERIMENTAL
Intervention: T12P12 group (telaprevir and peginterferon alfa‐2a without ribavirin for 12 weeks)
Number of subjects: 334
Study 19403903 — intervention group
Group type: EXPERIMENTAL
Intervention: T12PR24 group (telaprevir, peginterferon alfa‐2a, and ribavirin for 12 weeks, followed by peginterferon alfa‐2a and ribavirin for 12 more weeks)
Number of subjects: 334
Study 19403903 — intervention group
Group type: COMPARATOR
Intervention: PR48 group (control, peginterferon alfa‐2a and ribavirin for 48 weeks)
Number of subjects: 334
Study 17989272 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan twice a week for 16 weeks
Number of subjects: 52
Study 17989272 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care without exercise rehabilitation
Number of subjects: 52
Study 14508838 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fractionated radiation treatment arm
Number of subjects: 0
Study 14508838 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated radiation treatment arm
Number of subjects: 0
Study 14508838 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients attending college
Number of subjects: 0
Study 14508838 — intervention group
Group type: COMPARATOR
Intervention: All other education levels
Number of subjects: 0
Study 11199361 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily (QD)
Number of subjects: 310
Study 11199361 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg twice daily (BID)
Number of subjects: 310
Study 11199361 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily (QD)
Number of subjects: 310
Study 9406621 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linear amplification circuit (K-amp circuit)
Number of subjects: 45
Study 9406621 — intervention group
Group type: COMPARATOR
Intervention: Linear hearing aid
Number of subjects: 45
Study 9406621 — intervention group
Group type: COMPARATOR
Intervention: Previous aid
Number of subjects: 45
Study 9406621 — intervention group
Group type: COMPARATOR
Intervention: Comparison of preferences
Number of subjects: 45
Study 9406621 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression amplification circuit
Number of subjects: 45
Study 1589586 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (steady-state serum levels 0.9-1.3 mEq/L)
Number of subjects: 0
Study 1589586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3837123 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 55
Study 3837123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31888752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm of the trial
Number of subjects: 1618
Study 31888752 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 1618
Study 27760998 — intervention group
Group type: EXPERIMENTAL
Intervention: febuxostat 40 mg
Number of subjects: 20
Study 27760998 — intervention group
Group type: EXPERIMENTAL
Intervention: benzbromarone 50 mg
Number of subjects: 20
Study 27760998 — intervention group
Group type: EXPERIMENTAL
Intervention: febuxostat 20 mg and benzbromarone 25 mg (feb/ben)
Number of subjects: 20
Study 27760998 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 25645166 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 32
Study 25645166 — intervention group
Group type: COMPARATOR
Intervention: Control activity (e.g., reading newspaper)
Number of subjects: 32
Study 24018253 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (2 interactive workshops on the prevention of osteoporosis)
Number of subjects: 216
Study 24018253 — intervention group
Group type: COMPARATOR
Intervention: Control group (information by post)
Number of subjects: 216
Study 21336464 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Asthma Action Plans (WAAPs)
Number of subjects: 300
Study 20142183 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 2201
Study 20142183 — intervention group
Group type: COMPARATOR
Intervention: MED
Number of subjects: 2201
Study 20142183 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 2201
Study 18181335 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine (10 mg every 20 minutes, max 40 mg in the first hour, then 20 mg every 4 hours for up to 72 hours)
Number of subjects: 40
Study 18181335 — intervention group
Group type: COMPARATOR
Intervention: Intravenous terbutaline (initially infused at 10 microg/min, increased to max 25 microg/min, then switched to subcutaneous injection of 0.25 mg every 4 hours for 24 hours)
Number of subjects: 40
Study 15152270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally
Number of subjects: 24
Study 15152270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15152270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Mifepristone and Placebo)
Number of subjects: 24
Study 11282906 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear stress induced flow-dependent vasodilation in NC
Number of subjects: 32
Study 11282906 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial removal in NC
Number of subjects: 32
Study 11282906 — intervention group
Group type: EXPERIMENTAL
Intervention: NO synthase inhibitor Nomega-nitro-L-arginine (L-NNA) in NC
Number of subjects: 32
Study 11282906 — intervention group
Group type: COMPARATOR
Intervention: Flow-mediated dilation in HT
Number of subjects: 32
Study 11282906 — intervention group
Group type: COMPARATOR
Intervention: Flow-mediated dilation in HChol
Number of subjects: 32
Study 9001163 — intervention group
Group type: EXPERIMENTAL
Intervention: SR-NaF
Number of subjects: 316
Study 9001163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 8096703 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) alone at a maintenance dose of 250 mg every 6 h
Number of subjects: 265
Study 8096703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotherapy with acyclovir (ACV) at 800 mg every 6 h
Number of subjects: 265
Study 8096703 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 265
Study 3560381 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-practice model
Number of subjects: 2299
Study 31859541 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg (every 4 weeks or 8 weeks; first three doses every 4 weeks)
Number of subjects: 0
Study 31859541 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 0
Study 31704024 — intervention group
Group type: COMPARATOR
Intervention: Control (CON; 0.55 kg DM of a 20% CP and 20% fat MR per day)
Number of subjects: 4
Study 31704024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate (IL; 0.66 kg DM of a 26% CP and 17% fat MR per day)
Number of subjects: 4
Study 31704024 — intervention group
Group type: EXPERIMENTAL
Intervention: High (HL; 0.77 kg DM of a 26% CP and 17% fat MR per day)
Number of subjects: 4
Study 31704024 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive (AL; 0.87 kg DM of a 26% CP and 17% fat MR per day)
Number of subjects: 4
Study 31300494 — intervention group
Group type: COMPARATOR
Intervention: Oxygen 70 L/min, airway opened by laryngoscopy
Number of subjects: 100
Study 31300494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen 70 L/min with jaw thrust
Number of subjects: 100
Study 31300494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen 10 L/min with jaw thrust
Number of subjects: 100
Study 31300494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen 2 L/min with jaw thrust
Number of subjects: 100
Study 27788026 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (1 mg/kg/day)
Number of subjects: 328
Study 27788026 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (2 mg/kg/day)
Number of subjects: 328
Study 27788026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 27788026 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 328
Study 27788026 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 328
Study 26327768 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD group
Number of subjects: 4736
Study 26327768 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4736
Study 26327768 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight subjects
Number of subjects: 4736
Study 26327768 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese subjects
Number of subjects: 4736
Study 26327768 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD group stratified by BMI < 24 kg/m2
Number of subjects: 4736
Study 26327768 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD group stratified by 24 kg/m2 ≤ BMI < 28 kg/m2
Number of subjects: 4736
Study 26327768 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD group stratified by BMI ≥ 28 kg/m2
Number of subjects: 4736
Study 23238577 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang score ≥ 3 with serum HCO₃⁻ level ≥ 28 mmol/L
Number of subjects: 384
Study 23238577 — intervention group
Group type: COMPARATOR
Intervention: STOP-Bang score ≥ 3 without serum HCO₃⁻ level
Number of subjects: 384
Study 20704458 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium fast-disintegrating tablets (FDTs) 50 mg
Number of subjects: 0
Study 20704458 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial tablets of diclofenac potassium 50 mg
Number of subjects: 0
Study 20704458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19801929 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic prophylaxis (Ecologic 641)
Number of subjects: 141
Study 19801929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 17011374 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil (phase 1)
Number of subjects: 1109
Study 17011374 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose optimization and customized instructions (phase 2)
Number of subjects: 1109
Study 17011374 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 for initially unsatisfied patients
Number of subjects: 1109
Study 15001726 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal group therapy
Number of subjects: 11
Study 15001726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 11
Study 15001726 — intervention group
Group type: EXPERIMENTAL
Intervention: Group sessions for partners of persons with bipolar disorder
Number of subjects: 11
Study 15001726 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and family psychoeducation
Number of subjects: 11
Study 12193264 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium sulphate grafting
Number of subjects: 20
Study 12193264 — intervention group
Group type: COMPARATOR
Intervention: No calcium sulphate grafting (Control)
Number of subjects: 20
Study 9580524 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 0.5 mg/kg/day
Number of subjects: 45
Study 9580524 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 1 mg/kg/day
Number of subjects: 45
Study 9580524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 8114181 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA
Number of subjects: 87
Study 8114181 — intervention group
Group type: COMPARATOR
Intervention: PC
Number of subjects: 87
Study 3384469 — intervention group
Group type: EXPERIMENTAL
Intervention: High NaCl diet (400 mEq Na, 400 mEq Cl, 100 mEq K)
Number of subjects: 22
Study 3384469 — intervention group
Group type: COMPARATOR
Intervention: Low NaCl diet (10 mEq Na, 40 mEq Cl, 100 mEq K)
Number of subjects: 22
Study 31652094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg orally on days 1 to 21 of a 28-day cycle)
Number of subjects: 182
Study 31652094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 182
Study 31652094 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 182
Study 29653555 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mindfulness-based program
Number of subjects: 75
Study 29653555 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study 29653555 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment, retention, extent of questionnaire completion, usability and acceptability of, and adherence to the program
Number of subjects: 75
Study 28225205 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen at FiO2 of 0.50
Number of subjects: 11
Study 28225205 — intervention group
Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 11
Study 25179315 — intervention group
Group type: EXPERIMENTAL
Intervention: Para-right bundle branch (para-RBB) pacing
Number of subjects: 41
Study 25179315 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apex (RVA) pacing
Number of subjects: 41
Study 24325111 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented approach in combination with articulation approach
Number of subjects: 44
Study 24325111 — intervention group
Group type: COMPARATOR
Intervention: Articulation approach alone
Number of subjects: 44
Study 22136481 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg vitamin B12 and 400 μg folic acid daily (with 15 μg (600 IU) vitamin D included)
Number of subjects: 2919
Study 22136481 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet (with 15 μg (600 IU) vitamin D included)
Number of subjects: 2919
Study 19501753 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein drink (13% protein energy/87% carbohydrate energy)
Number of subjects: 28
Study 19501753 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium protein drink (25% protein energy/75% carbohydrate energy)
Number of subjects: 28
Study 19501753 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein drink (50% protein energy/50% carbohydrate energy)
Number of subjects: 28
Study 19501753 — intervention group
Group type: COMPARATOR
Intervention: Control drink (low energy, 328 kJ)
Number of subjects: 28
Study 16958121 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 87
Study 16958121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 12755456 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (225 mg daily)
Number of subjects: 14
Study 12755456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12755456 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (0, 12, 25, or 50 mg)
Number of subjects: 14
Study 11139672 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: General practitioners prescribed hepatitis C virus testing based on identified risk factors.
Number of subjects: 184
Study 11139672 — intervention group
Group type: COMPARATOR
Intervention: Group 2: General practitioners used posters and leaflets to assist in screening for hepatitis C virus.
Number of subjects: 184
Study 9090331 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1996
Study 9090331 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1996
Study 2037706 — intervention group
Group type: EXPERIMENTAL
Intervention: AICA-riboside (10, 25, 50, and 100 mg/kg doses)
Number of subjects: 6
Study 2037706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2037706 — intervention group
Group type: EXPERIMENTAL
Intervention: AICA-riboside (IV and oral administration)
Number of subjects: 6
Study 2037706 — intervention group
Group type: EXPERIMENTAL
Intervention: AICA-riboside (IV administration)
Number of subjects: 6
Study 2037706 — intervention group
Group type: EXPERIMENTAL
Intervention: AICA-riboside (oral administration)
Number of subjects: 6
Study 7264434 — intervention group
Group type: EXPERIMENTAL
Intervention: 170 micrometer standard blood filter
Number of subjects: 155
Study 7264434 — intervention group
Group type: COMPARATOR
Intervention: Saline-washed red blood cells
Number of subjects: 155
Study 7264434 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 to 25 micrometer microaggregate blood filters
Number of subjects: 155
Study 7264434 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrometer microaggregate screen filter
Number of subjects: 155
Study 31872901 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 196
Study 31872901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 30531489 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral modification + exercise from 0 to 3 months (CWT1)
Number of subjects: 120
Study 30531489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified behavioral modification (iBM)
Number of subjects: 120
Study 30531489 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral modification + exercise from 6 to 9 months (CWT2)
Number of subjects: 120
Study 30531489 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 120
Study 29212546 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support Systems (CDSS) with evidence-based order sets
Number of subjects: 0